Fibroblast membrane-camouflaged nanoparticles for inflammation treatment in the early stage.
10.1038/s41368-021-00144-2
- Author:
Lizhong SUN
1
;
Libang HE
1
;
Wei WU
2
;
Li LUO
2
;
Mingyue HAN
1
;
Yifang LIU
1
;
Shijie SHI
1
;
Kaijing ZHONG
1
;
Jiaojiao YANG
3
;
Jiyao LI
4
Author Information
1. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Cariology and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China.
2. Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering College of Chongqing University, Chongqing, China.
3. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Cariology and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China. jiaojiao.yang@scu.edu.cn.
4. State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Cariology and Endodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China. jiyaoliscu@163.com.
- Publication Type:Research Support, Non-U.S. Gov't
- MeSH:
Escherichia coli;
Fibroblasts;
Humans;
Inflammation/drug therapy*;
Nanoparticles
- From:
International Journal of Oral Science
2021;13(1):39-39
- CountryChina
- Language:English
-
Abstract:
Unrestrained inflammation is harmful to tissue repair and regeneration. Immune cell membrane-camouflaged nanoparticles have been proven to show promise as inflammation targets and multitargeted inflammation controls in the treatment of severe inflammation. Prevention and early intervention of inflammation can reduce the risk of irreversible tissue damage and loss of function, but no cell membrane-camouflaged nanotechnology has been reported to achieve stage-specific treatment in these conditions. In this study, we investigated the prophylactic and therapeutic efficacy of fibroblast membrane-camouflaged nanoparticles for topical treatment of early inflammation (early pulpitis as the model) with the help of in-depth bioinformatics and molecular biology investigations in vitro and in vivo. Nanoparticles have been proven to act as sentinels to detect and competitively neutralize invasive Escherichia coli lipopolysaccharide (E. coli LPS) with resident fibroblasts to effectively inhibit the activation of intricate signaling pathways. Moreover, nanoparticles can alleviate the secretion of multiple inflammatory cytokines to achieve multitargeted anti-inflammatory effects, attenuating inflammatory conditions in the early stage. Our work verified the feasibility of fibroblast membrane-camouflaged nanoparticles for inflammation treatment in the early stage, which widens the potential cell types for inflammation regulation.
